(0.32%) 5 116.06 points
(0.30%) 38 356 points
(0.37%) 15 987 points
(-0.95%) $83.05
(5.36%) $2.03
(0.34%) $2 355.20
(0.50%) $27.67
(4.18%) $960.65
(-0.27%) $0.932
(-0.44%) $10.98
(-0.58%) $0.796
(1.63%) $93.37
Live Chart Being Loaded With Signals
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs)...
Stats | |
---|---|
本日の出来高 | 10.80M |
平均出来高 | 4.95M |
時価総額 | 5.51B |
EPS | $0 ( 2024-02-28 ) |
次の収益日 | ( $0 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -22.44 |
ATR14 | $0.517 (1.29%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-07-11 | Blumenkranz Mark S. | Sell | 32 088 | Common Stock |
2023-07-11 | Blumenkranz Mark S. | Sell | 7 500 | Restricted Stock Units |
2023-07-11 | Blumenkranz Mark S. | Sell | 31 000 | Stock Option (Right to Buy) |
2023-07-11 | Blumenkranz Mark S. | Sell | 15 500 | Stock Option (Right to Buy) |
2023-07-11 | Blumenkranz Mark S. | Sell | 23 186 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-97.75 |
Last 100 transactions |
Buy: 73 584 | Sell: 6 010 653 |
ボリューム 相関
Iveric Bio Inc 相関
10 最も負の相関 | |
---|---|
CFFN | -0.899 |
ONEM | -0.88 |
SASR | -0.871 |
PFBC | -0.87 |
PBFS | -0.864 |
WABC | -0.858 |
SLN | -0.856 |
ISTR | -0.851 |
CMBM | -0.849 |
DZSI | -0.847 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Iveric Bio Inc 相関 - 通貨/商品
Iveric Bio Inc 財務諸表
Annual | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-1.450 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-1.450 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.120 |
FY | 2020 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.140 |
Financial Reports:
No articles found.
Iveric Bio Inc
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。